Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0000950170-25-034736 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-06 | 2025-03-04 | KPTI | Paulson Richard A. | Pres, CEO, Dir | S - Sale | $6.29 | -11.7K | 83.0K | -12% | -$73.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 11,694 | $6.29 | 82,984 | D | — | — | (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |